{"nctId":"NCT00295646","briefTitle":"Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid","startDateStruct":{"date":"1999-06"},"conditions":["Breast Cancer"],"count":1803,"armGroups":[{"label":"AZ (Arimidex+Zoledronate)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: anastrozole","Drug: zoledronic acid","Other: goserelin"]},{"label":"TZ (Tamoxifen+Zoledronate)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: tamoxifen","Drug: zoledronic acid","Other: goserelin"]},{"label":"AC (Arimidex Control)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: anastrozole","Other: goserelin"]},{"label":"TC (Tamoxifen Control)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: tamoxifen","Other: goserelin"]}],"interventions":[{"name":"tamoxifen","otherNames":["Nolvadex"]},{"name":"anastrozole","otherNames":["Arimidex"]},{"name":"zoledronic acid","otherNames":["Zoledronate, Zometa"]},{"name":"goserelin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Premenopausal, hormone receptor-positive patient\n* Histologically verified (minimally) invasive breast cancer, local radical treatment\n* 0-9 involved axillary lymph nodes (â‰¥ 10 histologically examined nodes)\n* Tumor stage: pT1b-3, yT0 or yT1a\n\nExclusion Criteria:\n\n* T1a, T4d, yT4; M1\n* Previous breast tumor irradiation\n* Previous or concurrent chemotherapy (except for preoperative chemotherapy)\n* Serum creatinine \\> 1.5 x UNL or creatinine clearance \\< 60 ml/min","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"19 Years","maximumAge":"59 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Comparison of Anastrozole vs Tamoxifen in Premenopausal Patients With Non-metastatic Breast Cancer With Respect to Disease-free Survival (DFS)","description":"DFS is defined as time from randomization to first occurrence of a local, regional, or distant recurrence, second primary carcinoma (including contralateral breast cancer), or death from any cause","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null}]}]}]},{"type":"PRIMARY","title":"Comparison of Zoledronate vs no Zoledronate in Premenopausal Patients With Non-metastatic Breast Cancer With Respect to Disease-free Survival (DFS)","description":"DFS is defined as time from randomization to first occurrence of a local, regional, or distant recurrence, second primary carcinoma (including contralateral breast cancer), or death from any cause","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Comparison of Anastrozole vs Tamoxifen in Premenopausal Patients With Non-metastatic Breast Cancer With Respect to Recurrence-free Survival (RFS)","description":"RFS is defined as time from randomization to first occurrence of a local, regional, or distant recurrence, second primary carcinoma (including contralateral breast cancer), or death from breast cancer","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Comparison of Zoledronate vs no Zoledronate in Premenopausal Patients With Non-metastatic Breast Cancer With Respect to Recurrence-free Survival (RFS)","description":"RFS is defined as time from randomization to first occurrence of a local, regional, or distant recurrence, second primary carcinoma (including contralateral breast cancer), or death from breast cancer","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Comparison of Anastrozole vs Tamoxifen in Premenopausal Patients With Non-metastatic Breast Cancer With Respect to Overall Survival (OS)","description":"OS is defined as time from randomization to death from any cause","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Comparison of Zoledronate vs no Zoledronate in Premenopausal Patients With Non-metastatic Breast Cancer With Respect to Overall Survival (OS)","description":"OS is defined as time from randomization to death from any cause","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":67,"n":450},"commonTop":["Bone pain","Other/minor (not categorized)","Arthralgia","Fatigue","Psychological disorder NOS"]}}}